Group 1: Earnings Performance - ARKO Corp. reported a quarterly loss of $0.12 per share, better than the Zacks Consensus Estimate of a loss of $0.17, but worse than a loss of $0.02 per share a year ago, indicating a 29.41% earnings surprise [1] - The company posted revenues of $1.83 billion for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 1.06%, but down from $2.07 billion year-over-year [2] - Over the last four quarters, ARKO has surpassed consensus EPS estimates only once and topped consensus revenue estimates just once [2] Group 2: Stock Performance and Outlook - ARKO shares have declined approximately 37.6% since the beginning of the year, compared to a decline of 4.3% for the S&P 500 [3] - The company's earnings outlook is mixed, with current consensus EPS estimates at $0.12 on $2.09 billion in revenues for the coming quarter and $0.08 on $7.95 billion in revenues for the current fiscal year [7] - The Zacks Rank for ARKO is currently 3 (Hold), indicating that shares are expected to perform in line with the market in the near future [6] Group 3: Industry Context - The Consumer Products - Staples industry, to which ARKO belongs, is currently in the bottom 28% of over 250 Zacks industries, suggesting potential challenges for stock performance [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact ARKO's stock performance [5]

HubSpot (HUBS) came out with quarterly earnings of $1.78 per share, beating the Zacks Consensus Estimate of $1.74 per share. This compares to earnings of $1.68 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 2.30%. A quarter ago, it was expected that this cloud-based marketing and sales software platform would post earnings of $2.19 per share when it actually produced earnings of $2.32, delivering a surprise of 5.94%.Over the ...

Group 1: Earnings Performance - The Trade Desk reported quarterly earnings of $0.33 per share, exceeding the Zacks Consensus Estimate of $0.25 per share, and up from $0.26 per share a year ago, representing an earnings surprise of 32% [1] - The company posted revenues of $616.02 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 7.27%, compared to year-ago revenues of $491.25 million [2] - Over the last four quarters, The Trade Desk has surpassed consensus EPS estimates four times and topped consensus revenue estimates three times [2] Group 2: Stock Performance and Outlook - The Trade Desk shares have declined approximately 52% since the beginning of the year, while the S&P 500 has only declined by 4.3% [3] - The current consensus EPS estimate for the upcoming quarter is $0.42 on revenues of $676.51 million, and for the current fiscal year, it is $1.79 on revenues of $2.84 billion [7] - The estimate revisions trend for The Trade Desk is currently unfavorable, resulting in a Zacks Rank 5 (Strong Sell) for the stock, indicating expected underperformance in the near future [6] Group 3: Industry Context - The Internet - Services industry, to which The Trade Desk belongs, is currently in the bottom 40% of over 250 Zacks industries, suggesting that the industry outlook can materially impact stock performance [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Core Viewpoint - U.S. Physical Therapy (USPH) reported quarterly earnings of $0.48 per share, exceeding the Zacks Consensus Estimate of $0.46 per share, but down from $0.51 per share a year ago, indicating a mixed performance in earnings [1] Financial Performance - The company achieved revenues of $183.79 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 3.60% and showing an increase from $155.68 million year-over-year [2] - Over the last four quarters, U.S. Physical Therapy has exceeded consensus EPS estimates two times and topped consensus revenue estimates four times [2] Stock Performance - U.S. Physical Therapy shares have declined approximately 19.3% since the beginning of the year, contrasting with the S&P 500's decline of 4.7% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating it is expected to perform in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.79 on revenues of $189.46 million, and for the current fiscal year, it is $2.63 on revenues of $752.89 million [7] - The estimate revisions trend for U.S. Physical Therapy is mixed, which may change following the recent earnings report [6] Industry Context - The Medical - Outpatient and Home Healthcare industry, to which U.S. Physical Therapy belongs, is currently ranked in the top 22% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]

Company Performance - Ferroglobe reported a quarterly loss of $0.20 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.12, and compared to break-even earnings per share a year ago, indicating a significant decline in performance [1] - The company posted revenues of $307.18 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 8.59%, and down from $391.85 million in the same quarter last year [2] - Over the last four quarters, Ferroglobe has surpassed consensus EPS estimates two times and topped consensus revenue estimates just once [2] Stock Outlook - Ferroglobe shares have lost about 9% since the beginning of the year, underperforming the S&P 500, which declined by 4.7% [3] - The current consensus EPS estimate for the coming quarter is $0.03 on revenues of $410.95 million, and for the current fiscal year, it is $0.23 on revenues of $1.61 billion [7] - The estimate revisions trend for Ferroglobe is currently unfavorable, resulting in a Zacks Rank 4 (Sell), indicating expected underperformance in the near future [6] Industry Context - The Mining - Miscellaneous industry, to which Ferroglobe belongs, is currently in the bottom 41% of over 250 Zacks industries, suggesting a challenging environment for stocks in this sector [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact investor sentiment towards Ferroglobe [5]

Core Insights - Idaho Strategic Resources, Inc. (IDR) reported quarterly earnings of $0.12 per share, missing the Zacks Consensus Estimate of $0.20 per share, and down from $0.17 per share a year ago, representing an earnings surprise of -40% [1] - The company posted revenues of $7.28 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 3.99%, and up from $5.9 million year-over-year [2] - The stock has increased approximately 56.9% since the beginning of the year, contrasting with the S&P 500's decline of -4.3% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.21 on revenues of $7 million, and for the current fiscal year, it is $0.78 on revenues of $28 million [7] - The estimate revisions trend for Idaho Strategic Resources is favorable, leading to a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Mining - Gold industry, to which Idaho Strategic Resources belongs, is currently in the top 20% of over 250 Zacks industries, suggesting a positive outlook for stocks within this sector [8]

NewAmsterdam Pharma Company N.V. (NAMS) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to loss of $0.62 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -8.89%. A quarter ago, it was expected that this company would post a loss of $0.48 per share when it actually produced a loss of $0.95, delivering a surprise of -97.92%.Over the last four quarters, the co ...

Company Performance - Haemonetics reported quarterly earnings of $1.24 per share, exceeding the Zacks Consensus Estimate of $1.22 per share, and up from $0.90 per share a year ago [1] - The company posted revenues of $330.6 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 1%, but down from $343.29 million year-over-year [3] - The earnings surprise for this quarter was 1.64%, and Haemonetics has surpassed consensus EPS estimates two times over the last four quarters [2] Stock Performance - Haemonetics shares have declined approximately 17.7% since the beginning of the year, compared to a decline of 4.3% for the S&P 500 [4] - The current Zacks Rank for Haemonetics is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [7] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $1.07 on revenues of $315.05 million, and for the current fiscal year, it is $4.98 on revenues of $1.32 billion [8] - The estimate revisions trend for Haemonetics is mixed, and changes in earnings expectations may occur following the recent earnings report [5][7] Industry Context - The Medical - Products industry, to which Haemonetics belongs, is currently ranked in the bottom 32% of over 250 Zacks industries, indicating potential challenges ahead [9]

Company Performance - Core Molding Technologies (CMT) reported quarterly earnings of $0.25 per share, missing the Zacks Consensus Estimate of $0.33 per share, and down from $0.43 per share a year ago, representing an earnings surprise of -24.24% [1] - The company posted revenues of $61.45 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 10.24%, and down from $78.15 million year-over-year [2] - Over the last four quarters, CMT has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Performance - CMT shares have declined approximately 6.8% since the beginning of the year, compared to a decline of -4.3% for the S&P 500 [3] - The current consensus EPS estimate for the coming quarter is $0.60 on revenues of $80.46 million, and for the current fiscal year, it is $1.72 on revenues of $302.57 million [7] Industry Outlook - The Rubber - Plastics industry, to which CMT belongs, is currently ranked in the top 38% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that industry performance can significantly impact stock performance [5][8]

Financial Performance - Novavax reported quarterly earnings of $2.93 per share, significantly exceeding the Zacks Consensus Estimate of $0.71 per share, and compared to a loss of $1.05 per share a year ago, representing an earnings surprise of 312.68% [1] - The company posted revenues of $666.66 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 215.04%, and compared to year-ago revenues of $93.86 million [2] Market Performance - Novavax shares have declined approximately 26% since the beginning of the year, while the S&P 500 has decreased by 4.3% [3] - The current consensus EPS estimate for the upcoming quarter is $0.07 on revenues of $149.29 million, and for the current fiscal year, it is $0.84 on revenues of $633.26 million [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which Novavax belongs, is currently ranked in the top 33% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Novavax's stock performance [5]